Skip to main content

Context Therapeutics, Inc. (CNTX)

NASDAQ: CNTX · Delayed Price · USD
+0.15 (2.94%)
After-hours:Oct 20, 2021 7:33 PM EDT
0.10 (2.00%)
At close: Oct 20, 4:00 PM

Company Description

Context Therapeutics® is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer.

Our development team is advancing a pipeline of innovative therapies with a primary focus on treating female cancers, which include, but are not limited to, breast, ovarian and endometrial cancer.

Our first program and lead product candidate, onapristone extended release (“ONA-XR”), builds upon a foundation of successful drug development by our management team and advisors in the field of female hormone-dependent cancers.

We believe that ONA-XR, in combination with current standard-of-care anti-estrogens, has the potential to significantly improve clinical outcomes. ONA-XR is currently being evaluated in three Phase 2 trials, one Phase 1b/2 trial and two Phase 0 biomarker pharmacodynamic trials in women with primary or metastatic breast, ovarian and endometrial cancers.

These trials are intended to establish safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity at the recommended Phase 2 dose of ONA-XR to guide potential advancement in Phase 3 development in 2023.

Context Therapeutics, Inc.
CountryUnited States
IPO DateOct 20, 2021
SectorHealth Care
CEOMartin Lehr

Contact Details

3675 Market Street, Suite 200
Philadelphia, PA 19104
United States

Stock Details

Ticker SymbolCNTX
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$5.00
CIK Code1842952
Employer ID32-0402377

Key Executives

Martin LehrCo-Founder, Chief Executive Officer and Director
Dr. Tarek SahmoudChief Medical Officer
Dr. Bill Rencher Ph.D.Head of CMC and Regulatory
Dr. Felix Kim Ph.D.Co-founder and Chair of Scientific Advisory Board
Eileen Kittrick CPAController
Alex Levit Esq.Chief Legal Officer and Corporate Secretary
Dr. Evan G. DickSenior Vice President of Research & Development